Abstract
The use of thiazolidinediones, drugs for type 2 diabetes that may also be useful for other chronic inflammatory disorders, is limited by fluid retention. Research in mice identifies a mechanism for this side effect and introduces a potential remedy (pages 861-866).
| Original language | English |
|---|---|
| Pages (from-to) | 822-824 |
| Number of pages | 3 |
| Journal | Nature medicine |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2005 |